

Consortium PSYCHIATRICUM

APPENDIX. SUPPLEMENTARY DATA TO:

Aleksandr Reznik, Timur Syunyakov, Aleksandr Mudrak, Nikolay Zakharov, Zhanna Popova, Anastasia Khoroshilova, Ilona Khurbatova, Alina Saifulina, Anton Eliseenko, Tatiana Matvievskaya, Angelina Khannanova.

Treatment of Depression with Vortioxetine and Second Generation Antipsychotics During the Period of Remission Formation in Schizophrenia (Interim Data Analysis).

Consortium Psychiatricum 2023; published online March 2023.

DOI: 10.17816/CP3728.

This appendix is a part of the original submission.
The appendix is posted as it was supplied by the authors.

Table S1. Results of test for contrasts between SGA and SGA + vortioxetine groups on the visit 2 and comparing to visit 1

Source		Type III Sum of Squares	df	Mean Square	f	Sig.	η^2p
CDSS	Visit 2 vs. Visit 1	250.233	1	250.233	21.535	<0.001	0.235
	Visit 3 vs. Visit 1	6.797	1	6.797	0.197	0.659	0.003
NSA5	Visit 2 vs. Visit 1	60.659	1	60.659	9.663	0.003	0.121
	Visit 3 vs. Visit 1	3.864	1	3.864	0.159	0.692	0.002
PDQ	Visit 2 vs. Visit 1	856.814	1	856.814	18.839	<0.001	0.212
	Visit 3 vs. Visit 1	6.689	1	6.689	0.057	0.812	0.001
PSP	Visit 2 vs. Visit 1	693.113	1	693.113	8.833	0.004	0.112
	Visit 3 vs. Visit 1	4165.393	1	4165.393	7.091	0.010	0.092
	Visit 3 vs. Visit 1	41120.591	70	587.437			

Table S2. Adverse events observed in the study

Adverse event	SGA + Vortioxetine <i>n</i> =39		SGA <i>n</i> =39	
	f	%	f	%
Drowsiness	6	15.4	6	15.4
Tremor	5	12.8	6	15.4
Akathisia	5	12.8	5	12.8
Poor of attention	5	12.8	5	12.8
Weight gain	5	12.8	6	15.4
Nausea	5	12.8	1	2.6
Dizziness	4	10.3	2	5.1
Anxiety	4	10.3	6	15.4
Weakness	3	7.8	4	10.3
Irritability	3	7.8	2	5.1
Itchy skin	3	7.8	-	-
Dry mouth	2	5.1	2	5.1
Headache	2	5.1	2	5.1
Yomiting	2	5.1	-	-
Dachycardia	2	5.1	3	7.8
Diarrhea	2	5.1	-	-
Hyperprolactinemia	2	5.1	3	7.8
Arousal	1	2.6	-	-
Exacerbation of schizophrenia	1	2.6	4	10.3
Worsening of depression	-	-	10	25.6

Note: *n* — number of patients in the sample; f — absolute number of patients with this sign.